Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldenberg

Showing results (101-110 of 296) with videos related to

Pageof 30
Sort By:
Bioconjugate Chemistry|August 3, 2011
High-yielding aqueous 18F-labeling of peptides via Al18F chelationChristopher A D'Souza, William J McBride, Robert M Sharkey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2007
Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargetingDavid M Goldenberg, Edmund A Rossi, Robert M Sharkey, et al.
Technology in Cancer Research & Treatment|July 21, 2005
Cancer therapy with radiolabeled and drug/toxin-conjugated antibodiesSerengulam V Govindan, Gary L Griffiths, Hans J Hansen, et al.
Nuclear Medicine and Biology|June 29, 2005
Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugatesSerengulam V Govindan, Rosana B Michel, Gary L Griffiths, et al.
Leukemia & Lymphoma|December 8, 2010
Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphomaRhona Stein, Cheryl Balkman, Susan Chen, et al.
Theranostics|June 28, 2012
Pretargeted molecular imaging and radioimmunotherapyDavid M Goldenberg, Chien-Hsing Chang, Edmund A Rossi, et al.
Molecular Cancer|March 11, 2014
Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancerDonglin Liu, Thomas M Cardillo, Yang Wang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancerRobert M Sharkey, George Hajjar, Dion Yeldell, et al.
International Journal of Oncology|May 5, 2005
Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16)David E Modrak, Habibe Karacay, Thomas M Cardillo, et al.
Cancer Research|October 17, 2008
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeuticsEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Pageof 30

Showing results (101-110 of 296) with videos related to

Sort By:
Pageof 30
Bioconjugate Chemistry|August 3, 2011
High-yielding aqueous 18F-labeling of peptides via Al18F chelationChristopher A D'Souza, William J McBride, Robert M Sharkey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2007
Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargetingDavid M Goldenberg, Edmund A Rossi, Robert M Sharkey, et al.
Technology in Cancer Research & Treatment|July 21, 2005
Cancer therapy with radiolabeled and drug/toxin-conjugated antibodiesSerengulam V Govindan, Gary L Griffiths, Hans J Hansen, et al.
Nuclear Medicine and Biology|June 29, 2005
Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugatesSerengulam V Govindan, Rosana B Michel, Gary L Griffiths, et al.
Leukemia & Lymphoma|December 8, 2010
Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphomaRhona Stein, Cheryl Balkman, Susan Chen, et al.
Theranostics|June 28, 2012
Pretargeted molecular imaging and radioimmunotherapyDavid M Goldenberg, Chien-Hsing Chang, Edmund A Rossi, et al.
Molecular Cancer|March 11, 2014
Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancerDonglin Liu, Thomas M Cardillo, Yang Wang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancerRobert M Sharkey, George Hajjar, Dion Yeldell, et al.
International Journal of Oncology|May 5, 2005
Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16)David E Modrak, Habibe Karacay, Thomas M Cardillo, et al.
Cancer Research|October 17, 2008
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeuticsEdmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Pageof 30